Loading...
XNYSBMY
Market cap116bUSD
Dec 23, Last price  
57.58USD
1D
0.44%
1Q
13.03%
Jan 2017
-1.47%
Name

Bristol-Myers Squibb Co

Chart & Performance

D1W1MN
XNYS:BMY chart
P/E
14.55
P/S
2.59
EPS
3.96
Div Yield, %
4.06%
Shrs. gr., 5y
4.89%
Rev. gr., 5y
14.81%
Revenues
45.01b
-2.50%
19,380,000,00019,207,000,00017,914,000,00019,348,000,00020,597,000,00018,808,000,00019,484,000,00021,244,000,00017,621,000,00016,385,000,00015,879,000,00016,560,000,00019,427,000,00020,776,000,00022,561,000,00026,145,000,00042,518,000,00046,385,000,00046,159,000,00045,006,000,000
Net income
8.03b
+26.84%
2,388,000,0003,000,000,0001,585,000,0002,165,000,0005,247,000,00010,612,000,0003,102,000,0003,709,000,0001,960,000,0002,563,000,0002,004,000,0001,624,000,0004,457,000,0001,007,000,0004,952,000,0003,439,000,000-8,995,000,0006,994,000,0006,327,000,0008,025,000,000
CFO
13.86b
+6.08%
3,176,000,0001,836,000,0002,083,000,0003,153,000,0003,707,000,0004,065,000,0004,491,000,0004,840,000,0006,941,000,0003,545,000,0003,148,000,0001,832,000,0002,850,000,0005,275,000,0005,940,000,0008,067,000,00014,052,000,00016,207,000,00013,066,000,00013,860,000,000
Dividend
Oct 04, 20240.6 USD/sh
Earnings
Feb 06, 2025

Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
URL
https://www.bms.com/
IPO date
Jul 05, 1929
Employees
34,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
45,006,000
-2.50%
46,159,000
-0.49%
46,385,000
9.09%
Cost of revenue
27,670,000
27,460,000
27,825,000
Unusual Expense (Income)
NOPBT
17,336,000
18,699,000
18,560,000
NOPBT Margin
38.52%
40.51%
40.01%
Operating Taxes
400,000
1,368,000
1,084,000
Tax Rate
2.31%
7.32%
5.84%
NOPAT
16,936,000
17,331,000
17,476,000
Net income
8,025,000
26.84%
6,327,000
-9.54%
6,994,000
-177.75%
Dividends
(4,744,000)
(4,634,000)
(4,396,000)
Dividend yield
4.45%
3.00%
3.14%
Proceeds from repurchase of equity
(5,155,000)
(8,001,000)
(6,287,000)
BB yield
4.83%
5.18%
4.49%
Debt
Debt current
3,281,000
4,400,000
5,117,000
Long-term debt
39,875,000
37,714,000
41,522,000
Deferred revenue
300,000
283,000
326,000
Other long-term liabilities
4,591,000
5,046,000
6,134,000
Net debt
28,377,000
30,804,000
29,947,000
Cash flow
Cash from operating activities
13,860,000
13,066,000
16,207,000
CAPEX
(1,209,000)
(1,118,000)
(973,000)
Cash from investing activities
(2,295,000)
(1,062,000)
(538,000)
Cash from financing activities
(9,416,000)
(16,962,000)
(16,224,000)
FCF
15,148,000
16,442,000
17,253,000
Balance
Cash
12,280,000
9,123,000
13,979,000
Long term investments
2,499,000
2,187,000
2,713,000
Excess cash
12,528,700
9,002,050
14,372,750
Stockholders' equity
27,567,000
24,571,000
22,904,000
Invested Capital
63,040,300
67,219,950
72,935,250
ROIC
26.00%
24.73%
23.02%
ROCE
22.84%
23.85%
20.22%
EV
Common stock shares outstanding
2,078,000
2,146,000
2,245,000
Price
51.31
-28.69%
71.95
15.40%
62.35
0.52%
Market cap
106,622,180
-30.95%
154,404,700
10.31%
139,975,750
-0.06%
EV
135,054,180
185,265,700
169,982,750
EBITDA
27,096,000
28,975,000
29,246,000
EV/EBITDA
4.98
6.39
5.81
Interest
1,166,000
1,232,000
1,334,000
Interest/NOPBT
6.73%
6.59%
7.19%